Navigation Links
QRxPharma Initiates Second Phase III Clinical Trial for its 'Dual Opioid' Pain Therapy
Date:12/13/2007

drugs, morphine and oxycodone, that have been shown to provide synergistic effects on pain relief with a significant reduction of total opioid dose and side effects.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a focused business strategy to expand the clinical utility and commercial value of marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk of failure, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialize its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, began Phase III clinical trials in November 2007. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: http://www.QRxPharma.com.


'/>"/>
SOURCE QRxPharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... researchers reveal that sudden, acute episodes of low back ... temperature, humidity, air pressure, wind direction and precipitation. Findings ... journal of the American College of Rheumatology (ACR), indicate ... with higher wind speed or wind gusts, but was ... Health Organization (WHO) nearly everyone experiences low back pain ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... captures heretofore hidden ways that cells are regulated, scientists ... breast cancer cells more likely to metastasize. , What,s ... part by blocking two other proteins that are normally ... disease processes could have unexpected ties. , The ... Nature , points to the possibility of new ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have found ... who are also depressed have difficulty sticking to ... particularly true for women, and screening and brief ... of treatment. The study and its findings are ... , Chronic obstructive pulmonary disease is a ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... line of defence in the threat of bio-terrorism according to ... international team of researchers from Cardiff University and University of ... well be an antidote to Bacillus anthracis more commonly know ... currently drink 165 million cups of tea, and the healing ...
... at Henry Ford Hospital today announced the start of ... international, multi-center clinical trial to explore an investigational treatment ... suffering with advanced emphysema. The study focuses on a ... in the lung for trapped air (one of the ...
... This release is available in French . ... by Universit Laval scientist Marc-Andr Sirard has identified genetic ... best chance of leading to successful pregnancy after in ... success rate of single embryo transfer and diminish the ...
... Angeles, March 12 --Combined positron emission tomography (PET) and ... more effective method to evaluate response to radiation therapy, ... study by researchers at the University of Southern California ... be published in the March issue of the journal ...
... and obesity training, state,s,largest Medicaid managed care plan now ... provide medical professionals the opportunity to become ... Well, Live Well program, CHARLESTON, W.Va., March 12 ... in the country in asthma prevalence,UniCare Health Plan of ...
... TSTF ) a national provider of healthcare and ... the Nasdaq Stock,Market that the Nasdaq Hearings Panel has ... Global Market pending the effectiveness of the,Company,s proposed reverse ... on February 7, 2008. The decision of the Panel ...
Cached Medicine News:Health News:Is a cup of tea really the answer to everything -- even anthrax? 2Health News:Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers 2Health News:Researchers develop a method to select eggs with the best chance of leading to successful pregnancy 2Health News:USC researchers find benefit for lymphoma patients in combined PET-CT scanning 2Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 2Health News:UniCare of West Virginia Providing Assistance for Asthma Education Training 3Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 2Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 3
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: